Pharmaceutical compositions comprising monoterpenes

Patent metadata

Field	Value
Publication number	US-11970436-B2
Application number	US-202217749293-A
Country	US
Kind code	B2
Filing date	May 20, 2022
Priority date	Mar 3, 2010
Publication date	Apr 30, 2024
Grant date	Apr 30, 2024

Abstract

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

First claim

What is claimed is:

1. A method for treating a central nervous system cancer, comprising administering intraarterially to a patient a therapeutically effective amount of (S)-perillyl alcohol,
wherein the (S)-perillyl alcohol has a purity of greater than about 98.5% (w/w).

2. The method of claim 1 , further comprising the step of delivering to the patient a chemotherapeutic agent.

3. The method of claim 2 , wherein the chemotherapeutic agent is a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, a receptor antagonist, a therapeutic antibody, or a vaccine.

4. The method of claim 1 , wherein the (S)-perillyl alcohol is in a pharmaceutical composition, and wherein the pharmaceutical composition comprises at least about 0.03% (v/v) of (S)-perillyl alcohol and at least about 2.6% (v/v) of a co-solvent.

5. The method of claim 4 , wherein the co-solvent is 1.3% (v/v) of a polyol and at least about 1.3% (v/v) of ethanol.

6. The method of claim 2 , wherein the chemotherapeutic agent is dimethyl-celecoxib (DMC), irinotecan (CPT-11), temozolomide, or rolipram.

Assignees

• Neonc Tech Inc
• Univ Southern California

Inventors

• Chen Thomas
• Levin Daniel
• Puppali Satish

Classifications

• C07C29/92 Primary

  by a consecutive conversion and reconstruction · CPC title

• A61K31/045

  Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates · CPC title

• A61K31/4188

  condensed with other heterocyclic ring systems, e.g. biotin, sorbinil · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title